Arginine deiminase and other antiangiogenic agents inhibit unfavorable neuroblastoma growth: Potentiation by irradiation

Authors

  • Hong Gong,

    1. Department of Hematology, Oncology and Endocrinology, Children's Hospital, University of Essen, Essen, Germany
    Current affiliation:
    1. Department of Cell Biology, Institute of Anatomy, University of Aarhus, Aarhus, Denmark
    Search for more papers by this author
    • Hong Gong and Christoph Pöttgen contributed equally to this work.

  • Christoph Pöttgen,

    1. Department of Radiotherapy, University of Essen, Essen, Germany
    Search for more papers by this author
    • Hong Gong and Christoph Pöttgen contributed equally to this work.

  • Georg Stüben,

    1. Department of Radiotherapy, University of Essen, Essen, Germany
    Search for more papers by this author
  • Werner Havers,

    1. Department of Hematology, Oncology and Endocrinology, Children's Hospital, University of Essen, Essen, Germany
    Search for more papers by this author
  • Martin Stuschke,

    1. Department of Radiotherapy, University of Essen, Essen, Germany
    Search for more papers by this author
  • Lothar Schweigerer

    Corresponding author
    1. Department of Hematology, Oncology and Endocrinology, Children's Hospital, University of Essen, Essen, Germany
    Current affiliation:
    1. Department of Pediatrics I, Children's Hospital, University of Goettingen, Goettingen, Germany
    • Department of Pediatrics I, Children's Hospital, University of Goettingen, Robert-Koch-Str. 40, 37075 Goettingen, Germany
    Search for more papers by this author
    • Fax: +49-551-39-6231


Abstract

In spite of aggressive therapy, children suffering from neuroblastoma have a poor prognosis. Therapeutic failure is most often observed in neuroblastomas with unfavorable features, including amplification/over-expression of the N-myc oncogene, rapid growth, effective angiogenesis and/or the tendency to metastasize. Here, we have used cultured human neuroblastoma cells with such features and we have examined whether antiangiogenic agents alone or in combination with tumor irradiation inhibit their angiogenesis and growth in vivo. We report that antiangiogenic agents (arginine deiminase, SU5416 and DC101) inhibit in vivo growth of neuroblastomas with unfavorable properties and that these effects are potentiated by simultaneous irradiation. Combination of either agent with irradiation leads to a reduction in the absolute number of tumor vessels and of perfused tumor vessels. Combination of arginine deiminase or DC101 with irradiation does not increase tumor hypoxia. Our data demonstrate for the first time that arginine deiminase suppresses the growth of unfavorable experimental neuroblastomas and that this effect is potentiated by irradiation. We suggest that antiangiogenesis alone or in combination with established therapeutic regimen may improve the outcome of unfavorable neuroblastomas in a clinical setting. © 2003 Wiley-Liss, Inc.

Ancillary